塞来昔布
Celecoxib;CELEBREX;4-[[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL]-1H-PYRAZOL-YL]BENZENESULFONAMIDE;4-[5-((4-METHYLPHENYL)-3-TRIFLUORPMETHYL)-1H-PYRAZOL-YL]BENENESULFONAMIDE;Celecoxib, 4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-yl]benzenesulfonamide;Benzenesulfonamide, 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl-;4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide;Celebra-;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide;Celexibn;IPTG;1-(4-sulphamoylphenyl)-3-trifluoromethyl-5-(p-tolyl)-pyrazole;4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide;4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfona;Celebrex,Celebra;Celecox;celexicob;Celocoxib;N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1yl]phenylsulfonyl]benzensulfonamide;YM 177;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;CJ-016377;CP-598107;SC-58635;YM-177;5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole;4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-yl]benzenesulfonamide;Celebra;SC 58635;Onsenal;YM177;Celecoxibum;SC58635;C17H14F3N3O2S;p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide;4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide;JCX84Q7J1L;CELECOXIB COMPONENT OF CONSENSI;Celecoxib [USAN];BCP9000507;BP-30217;HY-14398;CELECOXIB [MI];CELEBCOXIB;Z1258938406;KBio1_000893;Celecoxib, European Pharmacopoeia (EP) Reference Standard;NCGC00091455-07;D00567;AB00052396_11;NCGC00091455-05;ELYXYB-celecoxib;Spectrum3_001996;NCGC00254540-01;Celecoxib- Bio-X;NSC 758624;HMS3261A14;CELECOXIB [INN];KS-1041;L01XX33;Celebrex;Tox21_300599;UNM-0000305813;4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide;NCGC00091455-03;BC164295;AKOS015842517;KBio2_006048;DFN-15;NCGC00091455-02;Q-200816;Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-;CHEMBL118;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide;4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;GTPL2892;celecoxib;BCPP000290;AC-4228;CELECOXIB [HSDB];CELECOXIB [VANDF];MLS001195656;CELECOXIB [EP MONOGRAPH];SPECTRUM1503678;Celecoxib, >=98% (HPLC);HMS3884M07;KBio2_004919;MLS001304708;HMS502M15;CELECOXIB [WHO-DD];NCGC00259513-01;AI-525;Tox21_201964;NS00002556;CAS-169590-42-5;4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE;SPBio_001512;NSC719627;HMS2089L18;CELECOXIB [EMA EPAR];Benzenesulfonamide,4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-;J-010566;KBio2_003480;Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material;EX-A175;NINDS_000893;NSC 719627;EN300-119504;SR-01000837528-3;Celecoxib 400 mg;MFCD00941298;US8741944, Comparative Compound;Celecoxib, United States Pharmacopeia (USP) Referenc...